2 篇报道
Sagimet Biosciences, the strategic partner of Ascletis Pharma, has successfully dosed the first patient in a pivotal Phase III U.S. clinical trial evaluating denifanstat for moderate to severe acne. This milestone advances the therapeutic candidate closer to potential commercialization.
Ascletis reported positive preclinical data for its once-weekly oral peptide pipeline targeting obesity and metabolic disorders. The comprehensive portfolio covers four validated therapeutic targets with potential first-in-class fixed-dose combinations.
我们重视你的隐私. 我们使用必要的 Cookie 来保障网站运行;经你同意后,还会使用分析 Cookie 了解你的阅读偏好并改进网站。